key: cord-0927825-litmexme
authors: Al Alawi, Abdullah M.; Al Naamani, Zakariya
title: A Secondary Spontaneous Pneumothorax in a Patient with COVID-19: Case report
date: 2021-11-25
journal: Sultan Qaboos Univ Med J
DOI: 10.18295/squmj.4.2021.046
sha: 451d79f2765e6fc718aa8f4bd9c1c311bd830f1d
doc_id: 927825
cord_uid: litmexme

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, represents an unprecedented global threat. We report a 78-year-old male patient who presented to the Emergency Department at a tertiary care hospital in Muscat, Oman, in June 2020 with a one-day history of right chest pain and severe breathlessness. The patient was an ex-smoker and known to have idiopathic pulmonary fibrosis (IPF) with two previous pneumothoraces in the left lung. On presentation, the patient was breathless with an oxygen saturation of 90% on room air. Chest X-ray demonstrated bilateral lung infiltrates and right-sided pneumothorax. The patient tested positive for SARS CoV 2. A chest drain was placed which resulted in good resolution of the pneumothorax. The patient’s condition improved remarkably and he was discharged after 17 days of hospitalisation. To the best of the authors’ knowledge, this was the first case of pneumothorax reported in a patient infected with COVID-19 who was known to have underlying IPF.

S evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, represents an unprecedented global threat, with more than 12.3 million confirmed cases and 556,335 deaths at the time of the writing. 1 There have been many trials of therapeutic agents, but none of them have proved to be efficacious to date. 2, 3 Spontaneous pneumothorax is a very rare manifestation of COVID-19 and the exact mechanism is not fully understood. 4 This article reports the first case of spontaneous pneumothorax in a patient with idiopathic pulmonary fibrosis (IPF) who was admitted with COVID-19 pneumonia. The safety of using some of the therapeutic trial agents for treating COVID-19 in patients with pneumothorax is not clear. This article explores the possible underlying mechanism of pneumothorax in patients with COVID-19.

A 78-year-old male patient presented to the Emergency Department (ED) at a tertiary care hospital in Muscat, Oman, in June 2020 with a one-day history of right chest pain and severe breathlessness. There was no history of fever or cough. The patient was an ex-smoker and was known to have IPF. Additionally, he had had two spontaneous pneumothoraces involving the left lung four years prior without a clear precipitating factor. His previous chest computed tomography scan had demonstrated bilateral lung fibrosis and honeycombing and troponin levels were unremarkable. The clinical presentation and laboratory and radiological test results were not suggestive of acute exacerbation of IPF. Other differential diagnoses in this clinical setting, including myocardial ischaemia, were excluded.

The patient was started on 15 L oxygen via a nonrebreathing mask, enoxaparin (40 mg twice daily), intravenous ceftriaxone (2 gm daily for seven days) and azithromycin (500 mg daily for three days). He had an urgent chest drain insertion and a repeated chest X-ray showed a near-complete expansion of the rigid lung [ Figure 3A ]. In terms of the treatment for COVID-19, there were several trials at the treating hospital, including dexamethasone, convalescent plasma and anakinra. The patient consented to receive dexamethasone (6 mg daily for 10 days) and convalescent plasma (one dose) as part of a clinical trial and routine medical care.

The patient's condition continued to improve with gradual oxygen weaning. Dexamethasone was discontinued on the 10 th day; the patient was off oxygen support on the 14 th day, followed by the removal of the chest drain on the 17 th day. Repeated chest X-ray showed no reoccurrence of pneumothorax [ Figure  3B ]. Ideally, pleurodesis should have been performed during admission, but given the recent use of steroids, COVID-19 diagnosis and rapid resolution of the pneumothorax, pleurodesis was deferred. The patient remained well at the two-week follow-up visit and a repeated chest X-ray (day 30) showed stable bilateral IPF without evidence of pneumothorax. The patient's consent was obtained in order to publish this case report and the relevant laboratory and radiological findings. Total white blood count in × 10 9 /L 17. 

Spontaneous pneumothorax can complicate pulmonary infections with Pneumocystis jirovecii, mycobacteria, fungi or other microorganisms and the incidence varies with the frequency of these diseases in the population. 5, 6 Spontaneous pneumothorax is an unusual complication in patients with COVID-19; there are very few case reports and the majority of cases occur after the second week of infection. 4, [7] [8] [9] [10] [11] [12] Post mortem examination of COVID-19 cases demonstrated alveolar exudative inflammation and damage with thickened interalveolar septa, interstitial inflammation and fibrosis and platelet-fibrin thrombi small arterial vessels. 13, 14 Pneumothorax may occur due to the rupture of necrotic lung tissue caused by intense inflammation or ischaemia and the rupture of overdistended alveoli caused by bronchiolar inflammation. 15 Spontaneous secondary pneumothorax is a potential complication of interstitial lung disease (ILD) and it is associated with a poor outcome. 16 The current patient had ILD and he had had two previous pneumothoraces in the left lung, suggesting that he had a secondary rather than a primary pneumothorax. It was uncertain whether COVID-19 was a coincident or a precipitating factor for pneumothorax. Per local guidelines for treating patients with COVID-19, the patient received intravenous ceftriaxone and azithromycin. Additional treatments were available as a part of ongoing clinical trials at the treating hospital. The patient opted to receive dexamethasone as well as to be enrolled in the convalescent plasma trial. He made a remarkable recovery and was weaned off oxygen within two weeks. The follow-up chest X-ray, after removing the chest drain, showed no reoccurrence of the pneumothorax.

Pleurodesis was considered but deferred due to several factors, including the rapid resolution of the pneumothorax, the current COVID-19 infection and the recent use of steroids that may have slowed the healing process.

To the best of the authors' knowledge, this is the first report to describe a case of spontaneous secondary pneumothorax in a patient with IPF who was treated for COVID-19. It highlighted the complexity of decision-making in managing a common disease, i.e. pneumothorax, in the setting of an emerging infection. There are many uncertainties regarding the appropriateness of using specific COVID-19 treatments in patients with pneumothorax at this time, especially those who might require pleurodesis. Nevertheless, it is believed that the authors adopted a patient-centred approach to treatment that resulted in an excellent outcome.

SARS-CoV-2 infection may precipitate spontaneous pneumothorax in patients with underlying lung disease. The options for managing SARS-CoV-2 infection should consider the potential impact of the treatment of other active health issues. Additionally, this case illustrated potential uncertainties regarding the management of common conditions coinciding with SARS-CoV-2 infection. 

Remdesivir for the treatment of COVID-19 -Preliminary report

Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective

Tension pneumothorax in a patient with COVID-19

Pneumocystis jirovecii-related spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema in a liver transplant recipient: A case report

Pneumomediastinum and spontaneous pneumothorax as an extrapulmonary complication of COVID-19 disease

Secondary tension pneumothorax in a COVID-19 pneumonia patient: A case report

Mediastinal emphysema, giant bulla, and pneumothorax developed during the course of COVID-19 pneumonia

Spontaneous pneumothorax and subcutaneous emphysema in COVID-19 patient: Case report

COVID-19 with spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema

SARS-CoV-2 pneumonia with subcutaneous emphysema, mediastinal emphysema, and pneumothorax: A case report

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study

Postmortem examination of patients with COVID-19

COVID-19 with cystic features on computed tomography: A case report

Secondary spontaneous pneumothorax in idiopathic pulmonary fibrosis: Grim news